Le facteur de transcription RUNX2, pierre angulaire de l'hypertension artérielle pulmonaire
|Advisor:||Bonnet, Sébastien; Provencher, Steeve|
|Abstract:||Pulmonary arterial hypertension (PAH) is a pulmonary vascular disease that drives the narrowing of distal pulmonary arteries. Pulmonary artery narrowing leads to an increase in the pulmonary arterial pressure above 25 mmHg. In order to compensate this increased pressure, the right ventricle undergoes a pathological adaptation. Shortly, the right ventricle becomes unable to compensate this increase leading to right heart failure and patient’s death. So far, PAH treatment has allowed significant improvement for patient’s life quality but none of them can cure the disease. Distal pulmonary artery narrowing is due, at least in part, to the acquisition of a proliferative phenotype of the smooth muscle cell (SMC). Previously, the laboratory has demonstrated the down-regulation of the micro-RNA 204 in the SMC and its major role in the acquisition of this proliferative phenotype. Interestingly, the same down-regulation is observed in systemic vascular disease where it leads to the acquisition of a calcifying phenotype of the SMC by allowing the expression of the osteogenic transcription factor RUNX2. During my thesis, I investigated the role of RUNX2 up-regulation in pulmonary artery SMC allowed by the down-regulation of the micro-RNA 204. This project uncovered a critical role for RUNX2 in PAH, not only by participating to the acquisition of SMC proliferative phenotype but also by allowing the acquisition of a calcifying phenotype of the SMC. Furthermore, targeting RUNX2 in a Sugen/hypoxia rat model of PAH reverse histologic and heomodynamic PAH phenotype, making RUNX2 an attractive therapeutic target.|
|Document Type:||Thèse de doctorat|
|Open Access Date:||24 April 2018|
|Collection:||Thèses et mémoires|
All documents in CorpusUL are protected by Copyright Act of Canada.